Here are eight things for spinal surgeons to know for July 13, 2017.
Zimmer Biomet CEO David Dvorak exits after 10 years
David Dvorak stepped down as CEO of Zimmer Biomet and the company is conducting a search for his replacement. In the interim, Senior Vice President and CFO Daniel P. Florin will act as CEO. Mr. Dvorak also stepped down from the company's board of directors but will remain in an advisory capacity for an undisclosed timeframe. Read more about his departure here.
Rothman Institute merges with Trenton Orthopaedic Group
Philadelphia-based Rothman Institute merged with Trenton Orthopaedic Group in Mercerville, N.J. The new group will be called Trenton Orthopaedic Group at Rothman Institute. The merger will take effect in September 2017 and add four offices and 14 physicians to Rothman Institute. The new centers will provide services across various subspecialties, including joint replacement, spine, back and neck, sports medicine and orthopedic trauma.
Spinal Elements names new president and COO
Spinal Elements named Jason Blain president and chief operating officer. Mr. Blain will serves as a board of directors member and report to Spinal Elements CEO Chris Fair. As president and COO, Mr. Blain will be responsible for product development, quality, marketing, operations and regulatory compliance.
Dr. Brenda Fitzgerald at the helm of the CDC
HHS Secretary Tom Price, MD, reported Brenda Fitzgerald, MD, will serve as the new CDC director. Dr. Fitzgerald has been Georgia's public health commissioner since 2011. An obstetrician-gynecologist, Dr. Fitzgerald is the president-elect of the Association of State and Territorial Health Officials.
InVivo Therapeutics welcomes Dr. Richard Toselli as CMO
InVivo Therapeutics named Richard Toselli, MD, its chief medical officer on July 5. Dr. Toselli, a neurosurgeon specializing in spine, will oversee InVivo's clinical and regulatory strategy.
SeaSpine expects spinal instrumentation revenue to hit $16.6M for Q2
SeaSpine predicts revenue to hit between $34 million and $34.2 million for the second quarter of 2017, reflecting a 3 percent increase over the same period the year prior. The company's spinal instrumentation revenue will likely be $16.6 million for the second quarter of 2016 and the orthobiologics revenue will likely be around $17.6 million.
SpineGuard sees 19% US revenue growth, appoints new CEO
SpineGuard announced its first-half global revenue growth, the appointment of Stéphane Bette as CEO and its 2018 plans. In the first half of 2017, SpineGaurd sold 4,264 DSG units sold compared to 4,351 in the first half of 2016. In the U.S., SpineGuard posted a revenue growth of 19 percent.
AAOS advocates to lift restrictions on physician-owned hospitals
The American Association of Orthopaedic Surgeons is working with members of the Senate and House of Representatives to advance legislation that would lift restrictions on physician-owned hospitals. Read more here.